Home / Peptides / weight loss
Shop by goal

Best peptides for weight loss

Peptide protocols selected for weight loss and metabolic health. These target appetite, blood-sugar handling and body composition — best paired with nutrition and resistance training under clinician oversight.

Body Pharm MOTS-C 32

120,00 €
Multi-dose pen · 32 mg · 3 ml

Mitochondrial energy & endurance

MOTS-C 32 pen
Check eligibility More information
Compound guides
Class
Goals
Bundles

The most-researched peptides for weight management are the incretin compounds — Tirzepatide and the investigational Retatrutide — which act on the same appetite and metabolic pathways as branded GLP-1 medicines. Body Pharm also lists Tesamorelin and MOTS-c, studied for body composition and metabolism.

How these compounds are studied for weight

Tirzepatide is a dual GIP/GLP-1 agonist with the largest weight-loss data of any authorised incretin (SURMOUNT trials). Retatrutide adds a third receptor — glucagon — and posted the highest reductions yet seen in a Phase 2 obesity trial, though it remains investigational and is not an approved medicine. Tesamorelin is authorised specifically to reduce excess abdominal fat in HIV-associated lipodystrophy; MOTS-c is a mitochondrial peptide studied for metabolism.

How to choose

If you want an established, authorised titration schedule, Tirzepatide has one. Retatrutide is the frontier option for research use — more receptors, higher trial numbers, but no approved human dose. Compare them side by side before deciding, and remember Body Pharm pens are research products, not approved Zepbound, Mounjaro or Wegovy.

FAQ

Which peptide has the strongest weight-loss data?

In published trials, Retatrutide (triple agonist) reported the largest reductions, followed by Tirzepatide (dual agonist) and then single GLP-1 agonists like semaglutide. Retatrutide is still investigational; Tirzepatide is authorised.

Is Retatrutide approved?

No. Retatrutide is investigational — studied in clinical trials but not yet an approved medicine. Tirzepatide and Tesamorelin have authorised human dosing.

What is the difference between Tirzepatide and Retatrutide?

Tirzepatide targets two receptors (GIP + GLP-1); Retatrutide targets three (GIP + GLP-1 + glucagon). See our Retatrutide vs Tirzepatide comparison for a full breakdown.

Deep dive

Peptides for weight loss: where the evidence is strongest, and where it stops

The Body Pharm TeamUpdated 8 September 2026

This is the one goal in the catalogue with trial evidence of the kind used to authorise medicines — and it is also the goal where the gap between that evidence and what we supply is widest. Both facts belong on the same page, and most pages in this category state only the first. Batch certificates for every pen are published at /coa.

The incretin compounds carry the numbers. Everything else listed under this goal is studied for body composition on a much thinner basis. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022. PMID 35658024; SURMOUNT-1, NCT04184622; Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023. PMID 37366315; Spotlight on tesamorelin in HIV-associated lipodystrophy. PMID 22050344; Lee C et al. MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015. PMID 25738459

The evidence is not evenly distributed

Four compounds appear under this goal and their evidence differs by orders of magnitude.

Tirzepatide (what tirzepatide is) has completed Phase 3 programmes in two indications. SURMOUNT-1 ran 72 weeks and reported mean weight change of −15.0%, −19.5% and −20.9% at 5 mg, 10 mg and 15 mg weekly, against −3.1% for placebo. It holds an EU marketing authorisation.

Retatrutide (what retatrutide is) has one Phase 2 trial, 48 weeks, around 24% at the highest dose. No completed Phase 3. No authorisation anywhere.

Tesamorelin (what tesamorelin is, also listed under muscle) was studied in a specific population — HIV-associated lipodystrophy — and reduced visceral adipose tissue without a clinically significant change in subcutaneous fat. That is a fat-distribution finding in people with a defined metabolic condition.

MOTS-c (MOTS-c, explained) prevented diet-induced obesity in mice. There is no published human efficacy trial.

Listing all four under one heading is a navigational convenience. It is not a statement that they are comparably evidenced, and this page will not imply otherwise.

What the trial numbers describe

The percentages above come from randomised controlled trials with defined populations, a titration schedule, clinical supervision and, in SURMOUNT-1’s case, lifestyle intervention alongside the drug. They describe what happened to groups under those conditions.

They are not a forecast for an individual. Trial means conceal wide distributions — some participants far exceeded the average and some did not respond. And a result obtained under monitoring, at a titrated dose, with the surrounding trial protocol, is not automatically reproduced outside it.

Titration is the part most often dropped

Gastrointestinal adverse events — nausea, diarrhoea, vomiting, constipation — are the characteristic pattern for the incretin class and are dose-related. Every trial in the programme used slow upward titration over months rather than starting at a target dose, precisely because of that.

We do not publish a dosing schedule. The protocols are public in the papers cited above, and dose selection belongs with a qualified clinician who knows your history. For tirzepatide that point is sharper than usual: an authorised product with an approved schedule exists, and a clinician can prescribe it.

The regulatory split inside one goal page

Tirzepatide is an authorised medicine in the EU, supplied through licensed pharmacies against a prescription. Retatrutide is investigational. Tesamorelin was approved for a specific indication. MOTS-c holds no authorisation anywhere.

Four compounds, four different regulatory positions, one goal heading. Anyone comparing them on headline percentages alone is comparing numbers generated at completely different stages of development. We set the class out properly at incretin peptides, and the individual pairings at Retatrutide vs Tirzepatide and Tirzepatide vs Semaglutide.

What we can evidence

What is in the pen: identity, content, purity, sterility, batch traceability — third-party tested per lot, with the certificate reachable from the QR code on the pen. That is a manufacturing claim and we publish the document behind it.

What we cannot evidence is an outcome for you. The trials describe the molecules; they do not describe this supply route, and no page on this site will present them as though they do.

Related reading: why these compounds are not EMA-authorised, how to read a certificate of analysis.